Raloxifene: A Selective Estrogen Receptor Modulator for the Prevention of Osteoporosis

Abstract

Objective:

To review the efficacy and safety of the selective estrogen receptor modulator raloxifene hydrochloride in the prevention of osteoporosis.

Data Sources:

A MEDLINE search (January 1966–May 1998) and unpublished data obtained from the manufacturer were used to identify relevant studies and review articles. Additionally, bibliographies of selected articles were reviewed. Only English-language articles on human studies were obtained.

Study Selection:

Literature was reviewed to evaluate the pharmacology, pharmacokinetics, therapeutic use, adverse effects, and drug interactions of raloxifene. Additional relevant citations were used in the introduction material and clinical controversy section.

Data Extraction:

Clinical trials reviewing raloxifene for the prevention of osteoporosis were evaluated.

Data Synthesis:

Raloxifene hydrochloride is a partial estrogen agonist that displays both estrogenic and antiestrogenic effects. As a result of binding to estrogen receptors, raloxifene therapy, like estrogen treatment, causes positive changes in biochemical markers of bone turnover such as serum osteocalcin, serum alkaline phosphatase, urinary pyridinoline cross-links, and urinary calcium excretion. In addition, raloxifene increases bone mineral density. Furthermore, raloxifene reduces total serum cholesterol and serum low-density lipoprotein cholesterol. Raloxifene has no effect on serum high-density lipoprotein cholesterol. As a selective estrogen receptor modulator, raloxifene does not display the deleterious effects of estrogen in endometrial or breast tissue. The most common adverse effects are hot flashes and leg cramping.

Conclusions:

Clinical trials have found that raloxifene is effective in the prevention of osteoporosis, making the drug an alternative choice for the prevention of osteoporosis in patients who are concerned about the proliferative effects of estrogen replacement therapy on the endometrium or breast tissue. Raloxifene may not be a good alternative in women experiencing troublesome hot flushes during menopause. The use of raloxifene in the treatment of osteoporosis and in the prevention of breast cancer is currently being evaluated.

Get full access to this article

View all access options for this article.

References

Kanis

Devogelaer

Gennari

. Practical guide for the use of bone mineral measurements in the assessment of treatment of osteoporosis: A position paper of the European Foundation for Osteoporosis and Bone Disease. Osteoporosis Int 1996; 6: 256–61.

Lindsay

. Osteoporosis: A guide to diagnosis, prevention and treatment. New York: Raven Press, 1992:1–39.

Booher

. Estrogen supplements in menopause. Cleve Clin J Med 1990; 57: 154–60.

Ray

Chan

Thamer

Meton

III . Medical expenditure for the treatment of osteoporotic fractures in the United States in 1995: A report from the National Osteoporosis Foundation. J Bone Miner Res 1997; 12: 24–35.

Cummings

Rubin

. The future of hip fractures in the United States: Numbers, costs, and effects of postmenopausal estrogen. Clin Orthop 1990; 252: 63–6.

Krane

Holick

. Metabolic bone disease. In: Isselbacher

Braunwald

Wilson

Martin

Fauci

Kasper

, eds. Harrison's principles of internal medicine. 13th ed. New York: McGraw-Hill, 1994:2172–83.

Riggs

Melton

. Involutional osteoporosis. N Engl J Med 1986; 314: 1676–86.

Scheiber

Torregrosa

. Evaluation and treatment of postmenopausal osteoporosis. Semin Arthritis Rheum 1998; 27: 245–61.

Gibaldi

. Prevention and treatment of osteoporosis: Does the future belong to hormone replacement therapy? J Clin Pharmacol 1997; 37: 1087–99.

10.

Uitterlinden

Burger

Huang

Yue

McGuigan

Grant

Relation of alleles of the collagen type Iα1 gene to bone density and the risk of osteoporotic fractures in postmenopausal women. N Engl J Med 1998; 338: 1016–21.

11.

Lindsay

. Osteoporosis: A clinical overview of the diagnosis and therapy. J Musculoskel Med 1993; 10: 31–41.

12.

Netelvitz

. Estrogen therapy and osteoporosis: Principles and practice. Am J Med Sci 1997; 313: 2–12.

13.

Manolagas

Jilka

. Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis. N Engl J Med 1995; 332: 305–11.

14.

Horowitz

. Cytokines and estrogen in bone: Anti-osteoporotic effects. Science 1993; 260: 626–7.

15.

Genant

Baylink

Gallagher

. Estrogens in the prevention of osteoporosis in postmenopausal women. Am J Obstet Gynecol 1989; 161: 1842–6.

16.

Gambrel

. The true impact of HRT in menopause. Intern Med 1996; 17: 37–53.

17.

The Writing Group for the PEPI Trial. Effects of hormone therapy on bone mineral density: Results from the postmenopausal estrogen/progestin interventions (PEPI) trial. JAMA 1996; 276: 1389–96.

18.

Grady

Rubin

Petitti

Fox

Black

Ettinger

Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992; 117: 1016–37.

19.

Stampfer

Colditz

Willett

Manson

Rosner

Speizer

Postmenopausal estrogen therapy and cardiovascular disease. N Engl J Med 1991; 325: 756–62.

20.

Hulley

Grady

Bush

Furberg

Herrington

Riggs

Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998; 280: 605–13.

21.

Beresford

SAA

Weiss

Voight

McKnight

. Risk of endometrial cancer in relation to use of estrogen combined with cyclic progestagen therapy in postmenopausal women. Lancet 1997; 349: 458–61.

22.

Schneider

Barrett-Connor

Morton

. Timing of postmenopausal estrogen for optimal bone mineral density. The Rancho Bernardo Study. JAMA 1997; 277: 243–7.

23.

Lufkin

Wahner

O'Fallon

Hodgson

Kotowicz

Lane

Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Intern Med 1992; 117: 1–9.

24.

Jordan

. Biochemical pharmacology of antiestrogen action. Pharmacol Rev 1984; 36: 245–72.

25.

Mitlak

Cohen

. In search of optimal long-term female hormone replacement: The potential of selective estrogen receptor modulators. Horm Res 1997; 48: 155–63.

26.

Baker

Jaffe

. Clinical uses of antiestrogens. Obstet Gynecol Surv 1996; 51: 45–9.

27.

Gradishar

Jordan

. Clinical potential of new antiestrogens. J Clin Oncol 1997; 15: 840–52.

28.

Black

Jones

Falcone

. Antagonism of estrogen action with a new benzothiophene derived antiestrogen. Life Sci 1983; 32: 1031–6.

29.

Draper

Flowers

Neild

Huster

Zerbe

. Antiestrogenic properties of raloxifene. Pharmacology 1995; 50: 209–17.

30.

Bryant

Glasebrook

Yang

Sato

. A pharmacological review of raloxifene. J Bone Miner Metab 1996; 14: 1–9.

31.

Sato

Glasebrook

Bryant

. Raloxifene: A selective estrogen receptor modulator. J Bone Miner Metab 1994; 12 (suppl): S9–20.

32.

Clemens

Bennett

Black

Jones

. Effects of a new antiestrogen, keoxifene (LY156758), on growth of carcinogen-induced mammary tumors and on LH and prolactin levels. Life Sci 1983; 32: 2869–75.

33.

Delmas

Bjarnason

Mitlak

Ravoux

Shah

Huster

Effects of raloxifene on bone mineral density, serum cholesterol concentrations and uterine endometrium in postmenopausal women. N Engl J Med 1997; 337: 1641–7.

34.

Evans

Bryant

Sato

Turner

. Raloxifene is a tissue specific estrogen agonist (abstract). Calcif Tissue Int 1994; 54: 339.

35.

Baker

Draper

Paul

Allerheiligen

Giant

Shifren

Reproductive endocrine and endometrial effects of raloxifene hydrochloride, a selective estrogen receptor modulator, in women with regular menstrual cycles. J Clin Endocrinol Metab 1998; 83: 6–13.

36.

Prescribing information. Evista (raloxifene hydrochloride). Indianapolis: Eli Lilly and Company, 1997.

37.

Heaney

Draper

. Raloxifene and estrogen: Comparative bone remodeling kinetics. J Clin Endocrinol Metab 1997; 82: 3425–9.

38.

Draper

Flowers

Huster

Neild

Harper

Arnaud

. A controlled trial of raloxifene (LY139481) HCl: Impact on bone turnover and serum lipid profile in healthy post-menopausal women. J Bone Miner Res 1996; 11: 835–42.

39.

Stevenson

. Are changes in lipoproteins during HRT important? Br J Obstet Gynaecol 1996; 103 (suppl 13): 39–44.

40.

Westerveld

Koch

LAW

van Rijn

Erkelens

de Bruin

TWA

. 17 Beta-estradiol improves postprandial lipid metabolism in postmenopausal women. J Clin Endocrinol Metab 1995; 80: 249–53.

41.

Crook

Cust

Gangar

Worthington

Hillard

Stevenson

Comparison of transdermal and oral estrogen-progestin replacement therapy: Effects on serum lipids and lipoproteins. Am J Obstet Gynecol 1992; 166: 950–5.

42.

Budzar

Marcus

Holmes

Hug

Hortobagyi

. Phase II evaluation of LY156758 in metastatic breast cancer. Oncology 1988; 45: 344–5.

43.

Jordan

Glusman

Eckert

Lippman

Powles

Costa

Incident primary breast cancers are reduced by raloxifene: Integrated data from multicenter, double-blind, randomized trials in =12,000 postmenopausal women (abstract). Program and Proceedings of the 34th Annual Meeting, American Society of Clinical Oncology, Los Angeles, CA, May 19, 1998.

44.

Cummings

Norton

Eckert

Grady

Cauley

Knickerbocker

Raloxifene reduces the risk of breast cancer and may decrease the risk of endometrial cancer in post-menopausal women. Two-year findings from the Multiple Outcomes of Raloxifene Evaluation (MORE) Trial (abstract). Program and Proceedings of the 34th Annual Meeting, American Society of Clinical Oncology, Los Angeles, CA, May 19, 1998.

45.

1998 Drug topics red book. Montvale, NJ: Medical Economics Co., 1998: 308, 319, 494, 507.